VolitionRX Limited
VolitionRx Ltd is a U.S.-based epigenetics diagnostics company developing blood-based tests that use nucleosomes and related biomarkers to detect and monitor disease. Its portfolio includes the Nu.Q® family of tests and services for human and animal health, with commercialization through direct sales, distributors, and licensing partners across multiple countries.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueBlood-based tests for detecting and monitoring cancer in companion animals.
Assay technologies and services aimed at human diagnostic applications and partner development.
Research and assay services sold to partners and customers for biomarker discovery and validation.
Technology access, supply, and commercialization rights granted to diagnostic partners.
Customers
VolitionRx sells to diagnostic companies, reference laboratories, veterinary networks, and research partners that want biomarker-based tests they can commercialize or run in their own platforms. In animal health, customers include veterinary laboratories and distributors serving companion-animal clinics, while in human health the company works with specialized diagnostics groups developing assays for disease areas such as thrombosis and cancer. The business model depends on partners with established distribution, laboratory infrastructure, and regulatory/commercial reach.
Buy Nu.Q® Vet Cancer Test products to run cancer screening and monitoring workflows for companion animals.
License Volition's assay technology and supply agreements to commercialize tests on their platforms.
Purchase and distribute Nu.Q® Vet Cancer Test into regional animal-health markets.
Use Nu.Q® Discover and assay components to evaluate biomarker performance and clinical utility.
Evaluate Nu.Q® components for indications such as APS and other NETs-related diseases.
Strategy
VolitionRx's strategy is to monetize its biomarker IP through licensing, supply, and distribution partnerships rather than building a fully direct sales organization everywhere. The company is focused on expanding the Nu.Q® platform in companion animal health while also developing human diagnostic applications with established diagnostics companies that can provide regulatory, laboratory, and commercial infrastructure.
Partners provide distribution, laboratory capacity, and market access that Volition lacks at scale.
Companion-animal testing is the most visible commercialization path for the Nu.Q® platform.
Human disease indications could broaden the addressable market and deepen IP monetization.
Geography
VolitionRx operates as a multinational diagnostics business with commercialization and partner activity spanning the United States, Europe, and Asia. Its Nu.Q® Vet Cancer Test is available in over twenty countries, and the company relies on regional distributors and global partners such as IDEXX, Fujifilm Vet Systems, Werfen, and Hologic to extend market access. Geography matters because regulatory pathways, veterinary practice adoption, and partner networks differ by country and determine how quickly tests can be launched and scaled.
Risks
VolitionRx depends on external financing and partner execution, so commercialization risk is tied to both capital availability and third-party adoption. Its products are subject to regulatory, clinical validation, and reimbursement hurdles, while the company also faces typical diagnostics risks such as slow market uptake, competitive assay technologies, and dependence on a small number of strategic partners.
The company has not achieved sustained profitability and needs capital to fund operations and commercialization.
Exposure: Corporate liquidity and operating continuity
Commercial reach relies heavily on a limited number of licensing and distribution partners.
Diagnostic products must demonstrate utility and may require approvals or evidence generation before broad adoption.
Exposure: Human and veterinary assays
New blood-based tests can take time to gain routine use in veterinary and human workflows.
Exposure: Nu.Q® Vet Cancer Test and Nu.Q® Discover
Other diagnostics companies may offer alternative biomarker or liquid biopsy solutions.
Exposure: Epigenetic and NETs-related diagnostics
Accounting
Judgemental itemsLicensing, supply, and service agreements may recognize revenue over time or at milestones depending on performance obligations.
Impact: Affects timing of reported revenue and contract liabilities
Financing arrangements can include embedded features that must be remeasured at fair value.
Impact: Can create non-cash gains or losses in other income/expense
The value of patented technologies depends on commercialization success and future cash flows.
Impact: Could lead to impairment charges if expected use declines
Employee and director awards require valuation assumptions that affect operating expenses.
Impact: Impacts reported R&D, sales, and G&A costs
Similar listed companies
Publicly listed companies with a comparable business focus.
IDEXX Laboratories, Inc
IDXX · In Vitro & In Vivo Diagnostic Substances
IDEXX Laboratories develops and sells diagnostic products and services for veterinarians, livestock producers, water testing customers, and selected human point-of-care uses.
Ventyx Biosciences, Inc.
Pharmaceutical Preparations
Vincerx Pharma, Inc.
Pharmaceutical Preparations
NovaBridge Biosciences
NBP · Pharmaceutical Preparations
NovaBridge Biosciences is a global biotechnology company focused on discovering, developing, and partnering around differentiated therapeutic candidates in oncology and ophthalmology.
NeoGenomics, Inc
NEO · Services-Testing Laboratories
NeoGenomics is a U.S.-based cancer diagnostics company that provides oncology testing and consultative pathology services to help clinicians identify, classify, and monitor cancer.
Veracyte, Inc
VCYT · Services-Medical Laboratories
Veracyte is a U.S.-based molecular diagnostics company that develops and commercializes genomic tests used in cancer and other disease areas.
Last updated: 29/04/2026